A Personalized CYP2C19 Phenotype-Guided Dosing Regimen of Voriconazole Using a Population Pharmacokinetic Analysis
Open Access
- 10 February 2019
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 8 (2) , 227
Abstract
Highly variable and non-linear pharmacokinetics of voriconazole are mainly caused by CYP2C19 polymorphisms. This study aimed to develop a mechanistic population pharmacokinetic model including the CYP2C19 phenotype, and to assess the appropriateness of various dosing regimens based on the therapeutic target. A total of 1,828 concentrations from 193 subjects were included in the population pharmacokinetic analysis. A three-compartment model with an inhibition compartment appropriately described the voriconazole pharmacokinetics reflecting auto-inhibition. Voriconazole clearance in the CYP2C19 intermediate metabolizers (IMs) and poor metabolizers (PMs) decreased by 17% and 53% compared to that in the extensive metabolizers (EMs). There was a time-dependent inhibition of clearance to 16.2% of its original value in the CYP2C19 EMs, and the extent of inhibition differed according to the CYP2C19 phenotypes. The proposed CYP2C19 phenotype-guided initial dosing regimens are 400 mg twice daily (bid) for EMs, 200 mg bid for IMs, and 100 mg bid for PMs. This CYP2C19 phenotype-guided initial dosing regimen will provide a rationale for individualizing the optimal voriconazole therapy.Keywords
Funding Information
- National Research Foundation of Korea (2015R1C1A1A01054034)
This publication has 39 references indexed in Scilit:
- Multicenter Study of Voriconazole Pharmacokinetics and Therapeutic Drug MonitoringAntimicrobial Agents and Chemotherapy, 2012
- The Effect of Therapeutic Drug Monitoring on Safety and Efficacy of Voriconazole in Invasive Fungal Infections: A Randomized Controlled TrialClinical Infectious Diseases, 2012
- Integrated Population Pharmacokinetic Analysis of Voriconazole in Children, Adolescents, and AdultsAntimicrobial Agents and Chemotherapy, 2012
- Population Pharmacokinetics of Voriconazole in AdultsAntimicrobial Agents and Chemotherapy, 2012
- Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotypeBritish Journal of Clinical Pharmacology, 2009
- Population Pharmacokinetic Analysis of Voriconazole Plasma Concentration Data from Pediatric StudiesAntimicrobial Agents and Chemotherapy, 2009
- Comprehensive In Vitro Analysis of Voriconazole Inhibition of Eight Cytochrome P450 (CYP) Enzymes: Major Effect on CYPs 2B6, 2C9, 2C19, and 3AAntimicrobial Agents and Chemotherapy, 2009
- Voriconazole Therapeutic Drug MonitoringAntimicrobial Agents and Chemotherapy, 2006
- Pharmacokinetic/Pharmacodynamic Profile of VoriconazoleClinical Pharmacokinetics, 2006
- Some suggestions for measuring predictive performanceJournal of Pharmacokinetics and Biopharmaceutics, 1981